NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. The Company's biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. NewLink's small-molecule product candidates are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. The company merged with Lumos Pharma.